Drug repurposing, also known as drug repositioning or drug reprofiling, is a multifaceted approach that involves finding new uses for existing drugs beyond their original intended purpose. This strategy capitalizes on the wealth of information and experience already gathered about these drugs, potentially accelerating the drug development process and reducing costs. At its core, drug repurposing aims to uncover alternative therapeutic applications for drugs that have already undergone extensive testing for safety and efficacy in humans. This method offers several advantages, including shorter development timelines, lower risks, and potentially lower costs compared to traditional drug discovery methods. One of the key drivers behind drug repurposing is the recognition that many diseases share common underlying molecular pathways or targets, suggesting that drugs developed for one condition may be effective in treating others.
By systematically exploring these connections, researchers can identify promising candidates for repurposing, potentially bringing new treatment options to patients more quickly. Drug repurposing can involve a variety of approaches, including computational methods, high-throughput screening, and clinical observation. Computational methods utilize bioinformatics tools and databases to analyze molecular structures, pathways, and biological interactions to predict potential drug-disease associations. High-throughput screening involves testing large libraries of compounds against specific biological targets or disease models to identify potential candidates for repurposing.
Clinical observation relies on serendipitous discoveries or anecdotal evidence of drugs demonstrating unexpected therapeutic effects in patients with different conditions. Importantly, drug repurposing is not limited to small molecules; it can also encompass biologics, such as antibodies or peptides, as well as existing drug combinations. The process of repurposing a drug typically involves several stages, starting with the identification of a promising candidate and progressing through preclinical and clinical testing to establish safety and efficacy for the new indication.
Title : Advances in plasma-based waste treatment for sustainable communities
Hossam A Gabbar, Ontario Tech University, Canada
Title : Nanostructured biodevices based on carbon nanotubes and glyconanoparticles for bioelectrocatalytic applications
Serge Cosnier, Silesian University of Technology, Poland
Title : Carbon capture and storage: The impact of impurities in CO2 streams
Andy Brown, Progressive Energy Ltd, United Kingdom
Title : Supramolecular nano chemistries: Fighting viruses, inhibiting bacteria and growing tissues
Thomas J Webster, Hebei University of Technology, China
Title : Chemical engineering of vanadium and tantalum zeolites for application in environmental catalysis
Stanislaw Dzwigaj, Sorbonne Universite, France
Title : Disrupting TNF-α and TNFR1 interaction: Computational insights into the potential of D-Pinitol as an anti-inflammatory therapeutic
Ferran Acuna Pares, Universidad Internacional de la Rioja (UNIR), Spain